Who are Co-Latanoprost's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Medical abortion, Mifepristone + Misoprostol, Mifepristone and misoprostol, mifepristone and misopristol, Mifepristone plus two doses Misoprostol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/co-latanoprost.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Co-Latanoprost — Competitive Intelligence Brief

Co-Latanoprost (Co-Latanoprost) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog combination. Area: Ophthalmology.

marketed Prostaglandin analog combination FP receptor (prostaglandin F receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Co-Latanoprost (Co-Latanoprost) — Dr. David Yan. Co-Latanoprost is a fixed-dose combination of latanoprost (a prostaglandin F analog) and another agent that works synergistically to reduce intraocular pressure in glaucoma.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Co-Latanoprost TARGET	Co-Latanoprost	Dr. David Yan	marketed	Prostaglandin analog combination	FP receptor (prostaglandin F receptor)
Medical abortion	Medical abortion	Reproductive Health Training Center of the Republic of Moldova	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP)
Mifepristone + Misoprostol	Mifepristone + Misoprostol	Gynuity Health Projects	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor)
Mifepristone and misoprostol	Mifepristone and misoprostol	Gynuity Health Projects	marketed	Progesterone antagonist + prostaglandin analog combination	Progesterone receptor (mifepristone); prostaglandin E1 receptor (misoprostol)
mifepristone and misopristol	mifepristone and misopristol	Hadassah Medical Organization	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR) and prostaglandin E1 receptor (EP receptor)
Mifepristone plus two doses Misoprostol	Mifepristone plus two doses Misoprostol	Planned Parenthood League of Massachusetts	phase 3	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog combination class)

Dr. David Yan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Co-Latanoprost — Competitive Intelligence Brief. https://druglandscape.com/ci/co-latanoprost. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab